Timothy A. Springer, Director, 10% Owner at Cartesian Therapeutics, Inc. (RNAC), bought 77,397 shares at $18.35 ($1.4M) on 2024-12-19, disclosed to the SEC on 2024-12-23.
Open-market purchase of $1.4M RNAC by Director, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $17.39 | 11,303 | $197K | 13.9% |
| 2 | $17.39 | 11,303 | $197K | 13.9% |
| 3 | $18.35 | 10,529 | $193K | 13.6% |
| 4 | $18.35 | 10,529 | $193K | 13.6% |
| 5 | $18.93 | 3,376 | $64K | 4.5% |
| 6 | $18.93 | 3,376 |
| $64K |
| 4.5% |
| 7 | $18.94 | 21,800 | $413K | 29.1% |
| 8 | $19.00 | 5,181 | $98K | 6.9% |
| Total | $18.33 avg | 77,397 | $1.4M | 100% |
| Filing → |
| TECX | BUY | 2025-04-09 | $17.1M | — | Filing → |
| RNAC | BUY | 2025-03-20 | $2.7M | — | Filing → |
| TECX | BUY | 2025-02-07 | $47.0M | — | Filing → |